Figure 751: Alginate dressing versus dextranomer – mean rate of healing in patients improved > 40% (cm²/week)



Figure 752: Alginate dressing versus dextranomer – mean rate of healing (cm²/week)



Figure 753: Alginate dressing versus dextranomer – proportion of patients with an infection



Figure 754: Alginate dressing versus dextranomer – proportion of patients with hypergranulation



Figure 755: Alginate dressing versus dextranomer – proportion of patients with skin irritation



Figure 756: Alginate dressing versus dextranomer – proportion of patients with bleeding



Figure 757: Alginate dressing versus dextranomer – proportion of patients with pain



Figure 758: Alginate dressing versus dextranomer – proportion of patients with pruritus



Figure 759: Alginate dressing versus dextranomer –mortality

Study or Subgroup	Alginate Events	Alginate Total	Dextranomer Events	Dextranomer Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Sayag 1996	5	47	6	45	100.0%	0.80 [0.26, 2.43]
Total (95% CI)		**47**		**45**	**100.0%**	**0.80 [0.26, 2.43]**
Total events	5		6			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)



Figure 760: Silver dressing versus silver cream – mean percentage reduction in ulcer area

Study or Subgroup	Dressing Mean	Dressing SD	Dressing Total	Cream Mean	Cream SD	Cream Total	Weight	Mean Difference IV, Fixed, 95% CI
Chuangsuwanich 2011	36.95	56.13	20	25.06	56.13	20	100.0%	11.89 [-22.90, 46.68]
Total (95% CI)			**20**			**20**	**100.0%**	**11.89 [-22.90, 46.68]**

Heterogeneity: Not applicable
Test for overall effect: Z = 0.67 (P = 0.50)



Figure 761: Silver dressing versus silver cream –percentage reduction in PUSH score

Study or Subgroup	Dressing Mean	Dressing SD	Dressing Total	Cream Mean	Cream SD	Cream Total	Weight	Mean Difference IV, Fixed, 95% CI
Chuangsuwanich 2011	28.15	0	20	34.51	0	20		Not estimable
Total (95% CI)			**20**			**20**		**Not estimable**

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Figure 762: Silver dressing versus silver cream – proportion of people with adverse events

Study or Subgroup	Dressing Events	Dressing Total	Cream Events	Cream Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Chuangsuwanich 2011	0	20	0	20		Not estimable
Total (95% CI)		**20**		**20**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Figure 763: Silver dressing versus silver cream – mortality (all-cause)

Study or Subgroup	Dressing Events	Dressing Total	Cream Events	Cream Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Chuangsuwanich 2011	0	20	0	20		Not estimable
Total (95% CI)		**20**		**20**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Figure 764: Sugar versus dextranomer – proportion of patients completely healed



Figure 765: Sugar versus dextranomer – proportion of ulcers completely healed



Figure 766: Sugar versus dextranomer – proportion of patients improved



Figure 767: Sugar versus dextranomer – proportion of ulcers improved



Figure 768: Sugar versus different types of topical agents – proportion of patients completely healed



Test for subgroup differences: Not applicable

Figure 769: Sugar versus different types of topical agents – mean healing index



Test for subgroup differences: Not applicable

Figure 770: Honey versus ethoxydiaminoacridine and nitrofurazone – proportion of ulcers completely healed



Test for subgroup differences: Not applicable

Figure 771: Honey versus ethoxydiaminoacridine and nitrofurazone – mean percentage reduction in ulcer area



Test for subgroup differences: Not applicable

Figure 772: Honey versus ethoxydiaminoacridine and nitrofurazone – mean percentage reduction in PUSH score



Figure 773: Honey versus ethoxydiaminoacridine and nitrofurazone – proportion of people with adverse events



Figure 774: Honey versus ethoxydiaminoacridine and nitrofurazone – mortality



Figure 775: Platelet gel versus other treatment – proportion of pressure ulcers completely healed



Figure 776: Platelet gel versus other treatment – proportion of ulcers improved



Figure 777: Platelet gel versus other treatment – mean percentage reduction in ulcer volume



Figure 778: Hyaluronic acid versus sodium hyaluronic – mean percentage reduction in ulcer area (stage I)



Figure 779: Hyaluronic acid versus sodium hyaluronic – mean percentage reduction in ulcer area (stage II)



Figure 780: Hyaluronic acid versus sodium hyaluronic – time to 50% reduction in ulcer diameter (days) (stage I)



Figure 781: Hydraluronic acid versus sodium hyaluronic – time to 50% reduction in ulcer diameter (days) (stage II)



Figure 782: Hyaluronic acid versus sodium hyaluronic – time to 50% reduction in ulcer diameter (days) (stage III)



Figure 783: Zinc gauze dressing versus streptokinase-streptodornase – proportion of patients with skin reaction



Figure 784: Zinc gauze dressing versus streptokinase-streptodornase – proportion of patients with an infection



Figure 785: Zinc gauze dressing versus streptokinase-streptodornase – mortality (all-cause)



Figure 786: Hydrofibre versus resin salve – proportion of patients completely healed

Figure 787: Hydrofibre versus resin salve – proportion of ulcers completely healed

Figure 788: Hydrofibre versus resin salve – proportion of ulcers improved



Figure 789: Hydrofibre versus resin salve – proportion of ulcers worsened



Figure 790: Hydrofibre versus resin salve – proportion of patients with allergic skin irritation

Figure 791: Hydrofibre versus resin salve – mortality



Figure 792: Dextranomer versus chlorinated lime solution – Time to healing (defined as granulation and < 25% of original ulcer area) (days)



Figure 793: Dextranomer versus chlorinated lime solution – mortality



Figure 794: Collagen and foam versus foam dressing – proportion of people with pressure ulcers completely healed



Figure 795: Dextranomer versus chlorinated lime solution – mortality



Figure 796: Collagen and foam versus foam dressing – proportion of people with pressure ulcers completely healed



Figure 797: Collagen and foam versus foam dressing – mortality (all-cause)



I.2.9 Management of heel pressure ulcers

I.2.9.1 Various interventions for management of heel ulcers

Figure 798: Nimbus system versus Carewave system – proportion of people with pressure ulcers completely healed



Figure 799: Nerve growth factor versus placebo – reduction in ulcer area (mm2)



Figure 800: Hydrocolloid dressing versus collagen – proportion of people with pressure ulcers completely healed



Figure 801: Hydrocolloid dressing versus collagen - mean time to healing of pressure ulcers (weeks)



Figure 802: Ornithine alpha-ketoglutarate versus placebo – rate of complete healing of pressure ulcers at week 6 (cm2/day)



Figure 803: Ornithine alpha-ketoglutarate versus placebo – mean % reduction in pressure ulcer size



Figure 804: Ornithine alpha-ketoglutarate versus placebo – mean surface area reduction (cm2)



Figure 805: Ornithine alpha-ketoglutarate versus placebo – all-cause mortality